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Abstract: Interventional radiological percutaneous procedures are becoming all the more 
important in the curative or palliative management of elderly frail patients with multiple underlying 
comorbidities. They may serve either as alternative primary minimally invasive therapies or 
adjuncts to traditional surgical treatments. The present report provides a concise review of the 
most important interventional radiological procedures with a special focus on the treatment of the 
primary debilitating pathologies of the elderly population. The authors elaborate on the scientiﬁ  c 
evidence and latest developments of thermoablation of solid organ malignancies, palliative stent 
placement for gastrointestinal tract cancer, airway stenting for tracheobronchial strictures, endo-
vascular management of aortic and peripheral arterial vascular disease, and cement stabilization 
of osteoporotic vertebral fractures. The added beneﬁ  ts of high technical and clinical success 
coupled with lower procedural mortality and morbidity are highlighted.
Keywords: elderly, radiofrequency ablation, stents, aortic endografts, angioplasty, 
vertebroplasty
Introduction
Interventional radiology is a clinically-oriented specialty that employs image guidance 
in order to perform minimally invasive diagnostic and therapeutic procedures.1 
Technological developments of imaging equipment coupled with the advanced 
engineering of pinhole therapeutic applicators and minuscule endovascular instruments 
have fuelled worldwide adoption of transcatheter and percutaneous techniques in the 
treatment of various vascular and solid organ pathologies with increased efﬁ  cacy and 
reduced rates of morbidity and mortality.2
Elderly patients may be poor anesthetic candidates and are usually denied surgical 
treatments because of underlying comorbidities. In addition, elderly patients are in a 
higher risk of developing peri- and post-operative complications and usually require a 
longer and more cost-consuming recovery and rehabilitation period. Moreover, there 
is decreased pain sensitivity and perception with aging, which may further complicate 
therapy and management of the geriatric population. Elderly cancer patients, in 
particular, may suffer from increased drug toxicity and peri-operative morbidity and 
mortality because of age-related physiological decline and reduced functional reserve 
capacity.3–6
Front-line minimally invasive therapeutic procedures that are alternatives or may 
serve as adjuncts to traditional surgical treatments are becoming all the more important 
in the curative or palliative management of elderly frail patients with multiple comorbid 
conditions. The present report provides a concise review of several interventional 
radiological-guided procedures with a special focus on the treatment of the primary 
debilitating pathologies of the elderly population. In particular, the authors elaborate 
on thermoablation of solid organ malignancies, palliative stent placement for gas-
trointestinal tract cancer, endovascular management of aortic and peripheral arterial 
vascular disease, and cement stabilization of osteoporotic vertebral fractures (Figure 1). 
However, interventional radiological procedures in the elderly further include and are 
not limited to hepatobiliary interventions in malignancy, percutaneous urinary tract Clinical Interventions in Aging 2009:4 2
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procedures in obstructive nephropathy, carotid stenting of 
atherosclerotic extracranial carotid disease, interventional 
therapy of deep venous thrombosis and pulmonary embolism 
and various interventions for chronic pain relief. Amassed 
evidence is generally limited to uncontrolled observational 
series and prospective studies, because the associated 
comorbidities and low performance status of the geriatric 
population usually prohibits properly conducted head-to-head 
randomized controlled trials.
All procedures described in the present review paper 
are performed by appropriately trained interventional 
specialists, who are capable to carry out a successful 
intervention and take on responsibility and management 
of any procedure-related complications within a wide 
multidisciplinary team of clinical specialties that may include 
interventional radiologists, interventional cardiologists, 
vascular surgeons, thoracic surgeons, general surgeons, 
orthopedic surgeons and oncologists.
Cancer ablative therapies
Cancer remains the second leading cause of death with a 
well-recognized increasing burden of cancer in the elderly 
population. The risk of cancer development increases expo-
nentially with age above 60 years and almost two thirds of 
all new cancers afﬂ  ict people older than 65 years.7,8 Solid 
organ oncological interventions have a rapidly expanding role 
within interventional radiology. A wide range of radiological 
locoregional ablative techniques is available, which induce 
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tumorous cell death primarily through coagulative necrosis 
or ischemia. They may be broadly categorized into thermal 
ablation, mainly encompassing radiofrequency ablation, 
microwave ablation and cryoablation, chemical ablation by 
alcohol or acetic acid and transcatheter embolization with 
or without additional targeted chemotherapy.
At the moment, radiofrequency ablation (RFA), which 
was first applied in the early 1990s for the treatment 
of hepatic tumors,9 is by far the most widely adopted 
and commonly employed technique for percutaneous 
thermocoagulation of solid organ malignancies.1,2 RFA 
applicators with straight or expandable electrodes are 
introduced percutaneously under computed tomographic or 
ultrasonographic guidance into the center of the target tumor. 
Then, a high-frequency alternating current (460–500 kHz) 
is delivered through the lesion, which causes agitation of 
the tissue ionic molecules, which in turn produces frictional 
heat. Local tissue temperatures approach 100 °C resulting in 
coagulative necrosis of the tumor. Ablation treatment must 
include a 0.5–1 cm margin of healthy tissue around the target 
lesion in order to obliterate any microscopic satellite foci and 
avoid early local recurrence.2,10 The efﬁ  cacy of RFA may 
be limited by adjacent high-ﬂ  ow vascular structures, which 
act as a cooling circuitry (widely known as the heat-sink 
phenomenon) and increased tissue impedance in case of tis-
sue boiling and/or charring.10 Microwave thermocoagulation 
is an emerging technology, which depends on the application 
of an electromagnetic wave (around 900 MHz) through an 
electrode-antenna. Electromagnetic microwaves travel-
ling through tissue evoke agitation of ionic molecules and 
production of frictional heat, which results in tissue coagula-
tive necrosis. Of note, microwave ablation technologies have 
certain inherent advantages over RFA, since they operate 
independent of any electrical current convection and are 
less inﬂ  uenced by tissue impedance variabilities and heat 
sink phenomena. Microwave tumor ablation is gradually 
gaining place as a more versatile and efﬁ  cient method of 
tissue thermocoagulation, because it can achieve higher 
intratumorous temperatures and larger ablation zones more 
quickly than RFA.2,10,11
Primary hepatocellular carcinoma and metastatic liver 
disease (where local control can often improve life expec-
tancy) have both been treated with RFA and a survival 
beneﬁ  t has been demonstrated.12 A magnitude of prospective 
cohort studies in patients unﬁ  t for surgery for various reasons 
have provided the ﬁ  rst evidence base for more widespread 
application of liver radiofrequency ablation.13,14 Referred 
patients most commonly have inoperable disease or are unﬁ  t 
for liver surgical resection. RFA is best suited for localized 
primary hepatic tumors (one lesion less than 5 cm or three 
lesions less than 3 cm each).10 In a single-center RFA study 
of primary hepatocellular carcinoma in 206 cirrhotic patients, 
considered ineligible for transplantation or surgical resection, 
survival rates at 1, 3 and 5 years were 97%, 67%, and 41% 
on an intention-to-treat basis, respectively, after a median 
follow-up period of 2 years.15
Unlike surgery, RFA tumor ablation can be performed 
as a day case procedure under conscious sedation and has 
less morbidity and mortality.10 RFA may be repeated for 
new or recurrent disease and has a lower complication rate 
due to its minimally invasive nature.16 Reported mortality is 
0.5% and associated complication rates range from 8% to 
35%, mostly encompassing minor cutaneous burns, abscess 
formation and self-limiting post-ablation syndrome. RFA 
also has an intrinsic electrocautery effect, which potentially 
minimizes bleeding complications. Benign post-ablation 
biliary strictures and tumor seeding along the electrode tract 
remain rare.2,10
In parallel, there are reports of a survival beneﬁ  t in 
patients with hepatic colorectal metastases unﬁ  t for surgical 
metastasectomy and treated with RFA.12,17 Reported 
5-year survival rates compare very favorably with operable 
candidates who have undergone resection (30% with RFA vs 
39% with surgery).16 RFA also has the added beneﬁ  t of 
preserving bigger volumes of functioning liver tissue and 
thereby allowing for repeat sessions in the future, even in 
cases of multiple dispersed liver metastases.10 However, 
despite widespread adoption and incorporation of liver RFA 
into modern multidisciplinary management of liver cancer, 
more rigorous controlled trials are warranted to further 
elucidate its role in prolonging patient survival.13,14
There is also a growing body of evidence regarding 
thermocoagulation of renal cell carcinoma.10,11,18 RFA of renal 
cell carcinoma is an appealing curative treatment for small 
and exophytic tumors or when patients are too old and frail 
to undergo partial or complete nephrectomy (Figure 2).11,19 
However, large or central hilar tumors are more difﬁ  cult to 
ablate completely due to heat-sink effect from high blood 
ﬂ  ow at the renal hilum and increased risk of complications 
from the collecting system; mainly benign post-ablation 
strictures and urinoma formation.1,11
Lung cancer remains the leading cause of cancer death 
in men and women and is biologically characterized by an 
extended time period between exposure to carcinogenic 
chemicals and tumor development.20 Unfortunately, elderly 
people, in particular octogenarians, are less likely to be Clinical Interventions in Aging 2009:4 4
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offered surgical resection as a ﬁ  rst-line curative treatment 
option owing to either coexisting comorbid conditions or 
advanced disease at the time of diagnosis.20 Poor heat conduc-
tivity of the surrounding air makes lung lesions particularly 
suitable to RFA ablation, as heat remains localized into the 
lesion. Elderly surgically unﬁ  t patients with early (stage 1) 
nonsmall cell lung cancer (NSCLC) and those with limited 
metastases can be typically offered the treatment.10 However, 
published evidence of radiofrequency ablation of lung tumors 
is still limited to observational studies and case series that 
have demonstrated favorable safety proﬁ  le and low recur-
rence rates around 11%.21 A systematic literature review of 
lung RFA showed that the median progression-free interval 
ranged from 15 to 27 months (median = 21 months), and 
1-, 2- and 3-year survival rates were 63%–85%, 55%–65%, 
and 15%–46%, respectively.21 In view of growing evidence 
regarding lung stereotactic radiation therapy that also shows 
promising local control rates, randomized controlled trials 
between the two types of treatment are warranted.22
Finally, application of RFA is particularly appealling 
for pain management of intractable metastatic bone disease. 
Up to 85% of patients presenting with breast, prostate and 
lung cancer have evidence of bone metastases at the time of 
death.23 Relief of pain from these deposits is an important 
aspect of palliative care. Radiation therapy can take weeks to 
take effect and fails to relieve pain in up to 30% of patients.24 
There are several ablative techniques that have been used to 
treat bone metastases. Percutaneous ethanol injection causes 
coagulative necrosis through cellular dehydration. Severe 
pain from bone metastases may be treated by this method 
when conventional therapies such as opiate analgesia, chemo-
therapy and radiotherapy are ineffective, too slow acting or 
cause unacceptable side effects.25,26 RFA is particularly suited 
to bone metastases that are unsuitable for alcohol ablation 
due to their proximity to nerves or when intra-articular leak 
of alcohol may occur.26 A multicenter trial of patients with 
painful bone metastases in whom other therapies including 
radiotherapy and chemotherapy had failed found sustained 
pain relief in 95% of patients.27 Of interest, cryoablation 
is an alternative technique that freezes lesions to form an 
“ice-ball”. Similar results to RFA have been achieved in 
providing pain relief for bone metastases.28 Although the 
procedure takes more time than RFA, the extent of the 
cryoablation zone is more easily appreciated and monitored 
with conventional computed tomography, which allows the 
lesion to be more extensively treated without posing risks 
to surrounding structures.24 Complications of bone deposit 
ablation include damage to surrounding structures such as 
Figure 2 Example of radiofrequency ablation of renal cell carcinoma. (a–b) An 86-year-old male patient with solitary left kidney (history of unilateral nephrectomy for renal 
cell carcinoma (RCC) 5 years ago) presented with 2 small exophytic renal tumors (white arrow and arrowhead). Percutaneous biopsy conﬁ  rmed the histological diagnosis of 
RCC. (c–d) Percutaneous RFA of the two lesions under CT guidance (Cool-tip Valleylab RFA system, Tyco Healthcare, Hampshire, United Kingdom). Note the insertion of the 
RFA electrodes into the tumors (e–f) follow-up imaging show absence of contrast enhancement, congruent with complete tumor necrosis (white arrow and arrowhead).Clinical Interventions in Aging 2009:4 5
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nerve roots, bowel and bladder symptoms, formation of 
tumor-cutaneous ﬁ  stulae, and pathological fractures.24,27 If 
a pathological fracture is anticipated, then cementoplasty 
(deposition of cement inside the ablation area based on the 
same principles of vertebroplasty (see dedicated section of the 
present overview below) may be performed to stabilize the 
treated bone, usually the vertebrae or the acetabulum.10,25
A further ﬁ  eld of tumor ablative therapy includes arte-
rial intervention. Selective endovascular catheterization of 
tumors is performed with the aim of embolization or deliv-
ering regional chemotherapy. Embolization may be used to 
reduce tumor size or blood loss prior to surgery or to palliate 
patents that are poor surgical candidates and require symptom 
relief. Any hypervascular tumor such as metastastic renal cell 
or thyroid carcinoma may beneﬁ  t from embolization. Further 
analysis about the application of transarterial embolization 
techniques in cancer treatment is described elsewhere.2,29
Palliative stenting 
of the gastrointestinal tract
Aging remains a signiﬁ  cant risk factor for cancer of the ali-
mentary tract. The majority of esophageal, gastric, pancreatic 
and colorectal cancers are detected in elderly people; ie, older 
than 65 years.30 Moreover, commonly applied treatments of 
surgery, chemotherapy, radiation or combinations thereof can 
be associated with signiﬁ  cant complications and morbidity 
or may be intolerable in the setting of advanced age and 
underlying comorbidities. Unfortunately, more than 50% 
of esophageal and gastroduodenal cancer cases present with 
advanced disease and are not eligible for curative resection 
at the time of diagnosis.31,32 Minimally invasive radiologi-
cal stent placement is a palliative treatment option that is 
routinely offered nowadays to patients with unresectable 
tumorous obstructive disease of the gastrointestinal tract.
Stenting is actually an established form of treatment in 
a wide range of pathological conditions. Tracheobronchial 
stenting provides symptomatic relief from endoluminal 
disease or external tumor compression. Biliary and ureteric 
stenting are either used to palliate malignant obstruction or as 
a temporary measure in stone disease. Gastrointestinal (GI) 
stenting is used in upper GI; oesophageal and gastroduodenal; 
and lower GI; colonic; malignant obstructive pathology.
Stents are designed to maintain patency, avoid re-obstruction 
and minimize the risk of migration. Stents may be balloon-
expandable or self-expanding and are manufactured from 
stainless steel or other alloys. Nitinol (an alloy of nickel and 
titanium) self-expanding stents assume a predictable shape at 
body temperature when deployed and are generally preferred 
in the gastrointestinal tract. They provide radial force, which 
pushes against an obstructive lesion. Stents may be covered 
(usually with silicone and polyethylene covers) or uncovered, 
consisting of a nitinol mesh only.31–34 Covered stents usually 
resist tumor ingrowth and therefore prevent re-obstruction 
but are less stable and more rigid, requiring larger delivery 
systems and are more prone to migration. Uncovered stents are 
more ﬂ  exible and easier to deliver and deploy but are subject 
to tumor ingrowth. Many stents are also designed to prevent 
migration by having ﬂ  ared ends. For the purposes of this review 
the following is a discussion of the principles, advantages and 
complications of esophageal, gastroduodenal and colonic stent 
insertion. This technique exempliﬁ  es the beneﬁ  ts stenting can 
have over more traditional forms of treatment, particularly in 
an elderly population.
Palliative therapy in case of advanced esophageal car-
cinoma aims to maintain oral food intake and relieve pain, 
while avoiding aspiration, reﬂ  ux and regurgitation.31 Over 
the last decade, self-expanding metal stents have become the 
endoluminal treatment of choice for rapid relief of dysphagia 
in patients with advanced stage esophageal carcinoma.33,34 
Indications for esophageal stenting generally include 
tumorous esophageal obstruction or extrinsic compression, 
malignant esophageal perforation and tracheoesophageal 
ﬁ  stula, as well as refractory benign strictures.31,34 Esophageal 
stent insertion is usually performed after completion of 
chemotherapy and radiotherapy to avoid tumor shrinkage, 
which predisposes to stent migration. Esophageal stents are 
typically inserted transorally under conscious sedation.31 
The technical success rate of radiological esophageal stent 
insertion is almost 100% with impressive and rapid relief 
of dysphagia.34
Early procedure-related complications of esophageal 
stenting include lung aspiration, hemorrhage and esophageal 
perforation, which may occur in 10%–20% of the cases.31,35 
Hemorrhage is usually self-limited, perforation is uncommon 
and procedure-related mortality is very low, ranging from 
0% to 1.4%.35,36 Late recurrent dysphagia as a result of tumor 
overgrowth at the stent edges or ingrowth through the mesh 
of uncovered stents may be as high as 60%, and is usually 
treated with repeat co-axial placement of another stent.34,35 
Other delayed complications are mostly device-related and 
may include stent migration, stent torsion, stent fracture or 
tracheoesophageal ﬁ  stulation.35,37
Of note, percutaneous gastrostomy or gastrojejunostomy 
may be particularly helpful in patients with inoperable 
and unstentable carcinoma of the upper gastrointestinal 
tract that require prolonged enteral feeding. Disruption Clinical Interventions in Aging 2009:4 6
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of normal swallowing in the elderly because of stroke or 
degenerative neurological conditions is another indication 
of the procedure.38,39 With a combination of ultrasound and 
X-ray guided gastropexy various types of gastrostomy or 
gastrojejunostomy tubes may be inserted. The latter are 
preferred in cases of gastroesophageal reﬂ  ux or tumorous 
gastric outlet obstruction. Operators have to be extremely 
careful of liver laceration, perforation of the transverse colon 
and tube misplacement.39
Stenting can also be applied to alleviate malignant 
gastroduodenal and colonic obstruction. Patients with 
malignant gastric outlet or duodenal obstruction exhibit 
gastric distension, intractable vomiting and complete food 
intolerance leading to severely impaired quality of life.32 
They typically suffer from dehydration and electrolyte imbal-
ances and are at increased risk of aspiration pneumonia.40,41 
Large-diameter, self-expanding enteral stents can be inserted 
to relieve gastroduodenal obstruction and re-establish oral 
intake in patients with poor general condition. Nowadays, 
gastroduodenal self-expanding stenting has become the 
treatment of choice for rapid palliation of gastric outlet and 
duodenal obstruction in pre-terminal patients with advanced 
upper gastrointestinal malignant disease (Figure 3).32
Indications for gastroduodenal stenting include inoperable 
extrinsic or intrinsic malignant strictures due to stomach, 
duodenal, pancreatic and cholangiocarcinoma, lymphade-
nopathy and post-surgery anastomotic recurrent disease.32 
Gastrointestinal perforation with symptoms of peritonitis, 
peritoneal carcinomatosis, distal small bowel obstruction and 
uncorrectable coagulopathy are typical contra-indications for 
the procedure. The procedure is performed transorally under 
conscious sedation and ﬂ  uoroscopic guidance.32 Although 
large-diameter uncovered stents are routinely deployed, 
covered stents may be helpful to exclude malignant ﬁ  stulae 
Figure 3 Example of combined gastroduodenal and biliary stenting. (a) A 76-year-old female patient with inoperable duodenal adenocarcinoma encroaching the lumen of 
the duodenum (white arrows). (b) Transoral insertion of an 18-mm self-expanding stent (Niti-S duodenal stent, Pyramed, Esher, United Kingdom; TaeWoong Medical, Seoul, 
Korea) to relieve gastric outlet obstruction (white arrows). (c) Note the full expansion of the stent the following day (white arrows). (d) The next week the patient developed 
obstructive jaundice (likely from the stent compressing the tumor against the ampulla). (e–f) Percutaneous transhepatic cholangiography demonstrates marked dilatation of 
the biliary tree, which was treated with biliary stent insertion (Zilver, Cook Medical, Bloomington, United States) after ballooning through the duodenal stent mesh. Note the 
stent placed in the common bile duct and extending across the mesh of the duodenal stent (white arrowhead).Clinical Interventions in Aging 2009:4 7
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to adjacent organs. The technical success of gastroduodenal 
stent insertion approaches 100%, but clinical success 
to relieve symptoms and restore oral feeding is nearer 
90% because of either progressive distal disease or lack 
of functional stomach peristalsis (chronically obstructed 
stomach or tumor inﬁ  ltration of coeliac axis neural plexus).42 
The procedure is generally safe and well tolerated with a 
reported 0% mortality and less than 1% major complica-
tions including perforation and hemorrhage. Of note, early 
intraprocedural perforation or late perforation by erosion of 
the stent ends through the intestinal wall may be a surgical 
emergency.42 Similarly to esophageal stenting, stent migra-
tion occurs less frequently with uncovered stents, whereas 
reobstruction because of tumor ingrowth is treated with repeat 
co-axial stenting.32,41
Large bowel obstruction due to malignant colorectal 
cancer is also a common, major surgical emergency. Present-
ing patients are typically elderly with multiple co-morbidites 
including metabolic and electrolyte disturbances, intestinal 
ischaemia and sepsis. Emergency surgery has mortality up 
to 20%43 and Hartmanns procedures (resection and terminal 
colostomy) are suboptimal in elderly patients due to stoma 
care issues and many cases not being reversed.
Colonic stenting has a number of advantages related 
to emergency surgery being avoided in favor of elective 
surgery. This allows optimization of the patient, preopera-
tive radiological staging, multidisciplinary team discussion, 
neoadjuvant therapy and primary anastomosis to avoid a 
two-stage procedure. A recent analysis paper comparing 
colonic stenting as a bridge to surgery versus surgery alone 
for emergent left colonic obstruction found it to be more 
effective with reduced peri-procedural mortality and less 
likely to require a permanent colostomy.44 The beneﬁ  ts were 
greatest among those who were at highest risk of surgery. 
Stenting can also be used as a palliative measure in those 
patients that are unsuitable for surgery.
Colonic stenting requires minimal patient preparation. 
Most patients have a computed tomography (CT) scan and 
water-soluble enema to confirm the diagnosis, exclude 
perforation and assess the position and degree of stenosis. 
The procedure is carried out with the patient sedated in a 
left lateral position. Most left sided colonic lesions can be 
crossed with ﬂ  uoroscopic guidance using a combination of 
wires and catheters. Lesions more proximal than the splenic 
ﬂ  exure may require endoscopic assistance. The only absolute 
contraindications are perforation, distal rectal lesions (where 
a healthy landing zone above the anal sphincter mechanism 
cannot be obtained) and obstruction involving multiple 
sites, (most commonly found with pelvic cancers, serosal 
metastases and lymphadenopathy).45
A pooled safety and efﬁ  cacy analysis of prospective 
colonic stenting studies encompassing around 1, 200 patients 
demonstrated median technical and clinical success rates of 
94% and 91%, respectively, with a stent-related mortality of 
0.58%.43 The clinical success of colonic stenting as a bridge 
to surgery was 71.7%.43 Stenting is also more cost effective 
than traditional surgical options and palliative stenting has 
been shown to improve quality of life when compared with 
surgery.46 Shorter hospital stay and a cost reduction between 
approximately 20%–30% have also been observed.47 Colonic 
stenting is a relatively low-risk procedure with a mortality 
rate around 1%. When the stent is placed very near the 
anorectal canal tenesmus and transient incontinence can 
occur. Self-limiting haemorrhage is a minor complication, 
which is most likely related to the disease process itself.
Of note, performing physicians must be particularly 
vigilant of colonic perforation, which has an overall incidence 
of 4% and carries a 10% mortality rate.48,49 The risk increases 
with balloon dilatation of the diseased segment before stent 
deployment and excessive manipulation of guidewires 
(especially in the presence of diverticular disease).45 It 
can also occur as a late complication due to stent erosion, 
radiotherapy or chemotherapy.50 Migration of colonic stents 
has been reported in 12% of cases.43 Most stents migrate 
distally and pass through the anus, while symptomatic stents 
may be removed endoscopically. Finally, stent re-obstruction, 
which occurs in approximately 10% of the cases because of 
tumor ingrowth or overgrowth, can be treated by co-axial 
deployment of a second.48,51
Tracheobronchial stenting
Airway stenting may be applied to alleviate malignant or 
benign strictures of the tracheobronchial tree with impending 
asphyxia and death (Figure 4). The procedure may be either 
palliative for inoperable primary or secondary lung or neck 
neoplasms encroaching or compressing the airway, or tem-
porary for benign disease like inﬂ  ammatory and anastomotic 
strictures, post-intubation stenosis and tracheobronchomala-
cia.52–55 Patients with advanced malignant obstructions may 
present with hemoptysis and chest pain, severe dyspnea and 
stridor, being on the verge of suffocation. Given the limited 
life expectancy and poor performance status of these patients, 
urgent airway stenting is a sufﬁ  cient and effective palliative 
therapy.53,54 The procedure generally involves mutidisciplinary 
evaluation and execution from a team of oncologists, surgeons 
and interventional radiologists. A combination of rigid or Clinical Interventions in Aging 2009:4 8
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flexible endoscopy and plain fluoroscopy under general 
anesthesia is the safest approach for accurate stent deployment 
with minimal complications.52,53 Dedicated airway stents are 
typically self-expanding and may be uncovered or covered; 
composed either from plastic or metal alloys. Technical 
success rates are very high (98%–100%), but clinical success 
rates are somewhat lower, at the level of 88%–100% for benign 
conditions and 82%–92% for malignant disease.54 Similar to 
applications in other hollow organs, uncovered stents mostly 
suffer from neoplastic tissue ingrowth and covered ones from 
migration. Stent-related complications are more frequently 
encountered in the long-term treament of patients with benign 
airway stenoses and include decreased mucociliary clearance 
and sputum impaction, development of granulation tissue 
at the stent edges, stent migration and fracture.54,55 Further 
studies are necessary to identify speciﬁ  c patient groups who 
may have the most beneﬁ  t from stenting, as well as which 
type of stent is more suitable for the airways.56
Endografts for aortic vascular 
disease
Abdominal aortic aneurysm (AAA) is an age-related disease.57 
AAA patients over 80 years old are often denied open surgical 
repair because of underlying comorbidities.57,58 Advanced age 
on its own has also been identiﬁ  ed as an independent strong 
predictor of increased peri-operative death and post-operative 
adverse events following surgery of the thoracic or abdomi-
nal aorta.57,59 Endovascular aneurysm repair (EVAR) is 
now commonly used to treat elderly patients with amenable 
anatomy (Figure 5). Parodi and colleagues reported the ﬁ  rst 
successful clinical application of an appropriately engineered 
endograft for AAA exclusion in 1991.60 Ever since, the 
introduction of new devices with lower proﬁ  le and higher 
ﬂ  exibility and conformability allow continuous expansion of 
anatomical inclusion criteria and today more elderly patients 
may qualify for the procedure. New generation endograft 
devices are smaller, more durable and far easier to advance 
through tortuous iliac arteries and deploy across angulated 
AAA necks.1,58 Most importantly, evidence from of large 
multicenter randomized trials has demonstrated decreased 
peri-procedural mortality and morbidity of EVAR compared 
to open surgical repair series, although both procedure- and 
aneurysm-related mortality remain notably higher in older 
than in younger patients.57,61 Moreover, EVAR is related to 
signiﬁ  cantly less hospital stay and earlier patient ambulation 
and return to preoperative levels of activity.1
According to a meta-analysis, which included 1534 patients 
treated surgically and 1045 patients treated endovascularly for 
AAA, pooled mortality and morbidity was 7.5% and 31% after 
open repair compared to 4.6% and 11.5% following EVAR.57 
Nonetheless, long-term survival seems to be comparable for 
both techniques and device-related re-interventions are more 
common with EVAR.1,57 Thus, the actual beneﬁ  t of EVAR 
in terms of life years gained for elderly patients, especially 
for those over 80-years-old, remains questionable to date.58 
Overall, however, the current status of EVAR continues to 
be exceptionally robust and promising. Recently, fenestrated 
and branched customized endografts have been successfully 
applied for the endovascular exclusion of complex supra-
renal and juxtarenal thoracoabdominal aortic aneurysms in 
surgically unﬁ  t patients.62
In parallel, there has been tremendous progress in 
endovascular minimally invasive treatment of thoracic 
aortic disease.58 Following the early clinical enthusiasm with 
Figure 4 Example of palliative tracheal stenting. (a) A 67-year-old female with metastatic breast cancer and extensive mediastinal lymphadenopathy severely compressing and 
displacing the trachea (white arrow). (b) axial CT image, (c) plain chest X-ray, and (d) sagittal reformatted CT image show a self-expanding uncovered stent (Pyramed, Esher, 
United Kingdom) deployed in the trachea to restore luminal patency and avoid suffocation.Clinical Interventions in Aging 2009:4 9
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endograft exclusion of AAAs, Dake and colleagues pioneered 
the same endovascular technique in the management of 
descending thoracic aortic aneurysms in 1994.63 Ever 
since, a rapidly growing number of applications have been 
reported for a wide spectrum of thoracic aortic syndromes. 
These include and are not limited to acute and chronic aortic 
dissection, penetrating atherosclerotic ulcer, traumatic aortic 
transection, mycotic aneurysm, and rupture.64,65 Although 
high-level clinical evidence from randomized controlled 
trials is still missing, elderly and frail patients are probably 
the ones to enjoy the most clinical beneﬁ  t in this new era of 
endovascular treatment of thoracic aortic diseases.66
Infrapopliteal angioplasty for critical 
limb ischemia
Critical limb ischemia (CLI) refers to limb-threatening 
peripheral atherosclerosis, and is typically characterized by 
multilevel, infrainguinal and infrapopliteal arterial occlusive 
disease.67–69 CLI has an estimated incidence of 500–1000 per 
million per year and primarily afﬂ  icts elderly patients with 
diabetes mellitus.70 Almost 170 million people suffer from 
diabetes worldwide with a projection to double by 2030.71 
Diabetic foot ulcers affect approximately 15% of all 
diabetics and are identiﬁ  ed in 84% of diabetes-related lower 
extremities’ amputations owing usually to a combination 
of neuropathy and CLI symptoms.71,72 Deﬁ  ciencies in more 
than 100 physiologic factors implicated in the cascades of 
angiogenesis, tissue regeneration and normal wound heal-
ing have been identiﬁ  ed in diabetic ischemic feet.71 The 
presence of diabetes mellitus accentuates the risk of CLI by 
four times and diabetic patients with CLI are ten times more 
prone to amputation than normoglycemic patients.73 If CLI 
is left untreated, it has a dispiriting natural course with an 
estimated 25% major amputation and 25% cardiovascular 
Figure 5 Example of endograft insertion for abdominal aortic aneurysm. (a) An 83-year-old male with an incidental ﬁ  nding of a 6.7-cm infrarenal abdominal aortic aneurysm 
extending to the aortoiliac bifurcation (white arrow). (b) Aneurysm was successfully excluded with transfemoral insertion of a bifurcated endograft device (Zenith AAA 
Endovascular Graft, Cook Medical, Bloomington, United States). Note the suprarenal ﬁ  xation of the device (white arrowhead) and the distal landing in the common iliac 
arteries (white arrows) to minimize risk of endoleak.Clinical Interventions in Aging 2009:4 10
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mortality rate at 1 year.70 In the interest of preventing limb 
loss or minimizing the extent of pre-planned amputation, 
CLI patients must undergo urgent percutaneous or surgical 
recanalization of the peripheral arteries.
Although bypass surgery remains the cornerstone of CLI 
treatment, the majority of the patients are rendered ineli-
gible because of diffuse infrapopliteal arterial occlusions, 
absence of suitable vein grafts and multiple underlying 
comorbidities.72,73 On the other hand, modern developments 
in endovascular instruments and the growing skills of vas-
cular interventional radiologists have driven a paradigm 
shift in CLI treatment towards percutaneous transfemoral 
infrapopliteal angioplasty and stenting.69,73 Compared to 
surgery, angioplasty is a minimally invasive procedure with 
a clear beneﬁ  t of reduced complications and peri-procedural 
adverse events, especially in the frail patient cohort of 
elderly octogenarians.69,74 In addition, it may be repeated as 
necessary and more than one occluded vessels to the foot 
may be recanalized.
Amassed evidence regarding the overall effectiveness and 
safety of infrapopliteal angioplasty supports its application 
as ﬁ  rst-line treatment option for infrapopliteal obstructive 
arterial disease for CLI treatment.67,69,72 The primary goal of 
infrapopliteal angioplasty is to restore at least one straight line 
of blood vessel to the distal foot (Figure 6). The secondary 
objective is to preserve the patency of the treated lesion for 
as long as possible to avoid recurrence of CLI. In the major-
ity of the cases infrapopliteal angioplasty is combined with 
more proximal endovascular procedures. Occasionally, it 
may be applied in tight distal anastomotic lesions of bypass 
grafts to avoid early graft failure and thrombosis. Reported 
complications rates range from 3% to 11% and include 
puncture site hematomas, vessel perforation, dissection and 
distal embolism or thrombosis, which may be successfully 
Figure 6 Example of infrapopliteal angioplasty and stenting for critical ischemia. (a) Angiogram of infrapopliteal arteries of a 79-year-old diabetic male with left leg critical limb 
ischemia (nonhealing heel ulcer). Note the long occlusions of the tibioperoneal-posterior tibial (white straight line) and peroneal (white dotted line) arteries. (b) Angiograms 
after initial balloon angoplasty and (c) after additional drug-eluting stenting (CYPHER Drug-eluting stent, Cordis, Waterloo, Belgium) show successful recanalization of both 
arteries to the distal foot. The patient experienced immediate relief of rest pain and the ulcer healed gradually within three months.Clinical Interventions in Aging 2009:4 11
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managed by endovascular means. The 30-day peri-procedural 
mortality rate is less than 1.7%.69
A random effects meta-regression analysis of 18 studies 
published between 1984 and 1997 and including 1280 patients 
treated with infrapopliteal balloon angioplasty reported overall 
limb salvage rates of 79% at 1 year and 74% after 2 years.75 
A more recent meta-analysis of 30 studies published between 
1990 and 2006 reported 3-year limb salvage and patient 
survival probabilities of 82.4% and 68.4%, respectively.76 In 
comparison the 5-year limb salvage rates using autogenous 
veins for infrapopliteal bypasses range from 73% to 81%.77 
Unfortunately, short-term angiographic vascular restenosis 
is high, and infrapopliteal occlusion reportedly recurs in 
as many as 50% of the cases by 1 year resulting in a high 
frequency of repeat procedures.72,73,78 Although infrapopliteal 
application of bare metal stents is safe and feasible, it is 
associated with signiﬁ  cant neointimal hyperplasia and early 
restenosis.67–69,79 Motivated by the success of drug-eluting 
stents in the coronary arteries, researchers have applied them 
in the infrapopliteal arteries to forestall vascular restenosis 
and prolong amputation- and reintervention-free survival 
of CLI patients. Recently published data about application 
of drug-eluting stents (DES) show favorable clinical results 
at 6 and 12 months with signiﬁ  cantly higher angiographic 
patency and less clinically driven re-interventions when 
compared to bare metal stents.72,73,78,80,81
Vertebroplasty for osteoporotic 
vertebral fractures
Osteoporosis is a signiﬁ  cant cause of morbidity and mortality 
in an aging population. Osteoporotic vertebral fractures 
are a cause of severe back pain and immobility in elderly 
patients. Consequences include loss of independence and 
increased risk of deep venous thrombotic and respiratory 
complications. Fractures can occur after minor trauma and 
may involve acute collapse or micro fractures without a 
compressive component. It is believed that pain is related 
to compressive loads causing movement of fracture frag-
ments. This results in inﬂ  ammatory changes and irritation 
of pain receptors.82 Pathological fractures secondary to 
vertebral body metastases and multiple myeloma are also 
important causes for severe back pain in elderly patients. 
Rapidly relieving pain to restore function and quality of life 
is an important goal of palliative therapy. These patients are 
particularly challenging. They often fail traditional medical 
therapy, are susceptible to the adverse effects of opiates, 
require more rapid relief than chemotherapy and radiotherapy 
can offer (and which can also be poorly tolerated) and are 
frequently surgically unﬁ  t. The role of both vertebroplasty 
and kyphoplasty lies in the management of those in whom 
medical management including opiate analgesia, bed rest and 
bracing have proved unsatisfactory or inadequate.
Vertebroplasty is a minimally invasive technique, which 
can be performed under conscious sedation as a day case 
procedure. It is used to treat pain related to vertebral body 
fractures or malignant inﬁ  ltration. In patients with neurologi-
cal symptoms it may also be used as an adjunct to surgery 
to provide vertebral stabilization prior to spinal decompres-
sion.83 Fluoroscopy (in some centres used in conjunction with 
computed tomography) is used to guide a needle through the 
posterior aspect of the vertebral body, using most commonly 
a transpedicular approach. Cement is injected under careful 
ﬂ  uoroscopic guidance and uni- or bipedicular injections can 
be applied depending on operator preference, positioning of 
the needles and success of cement injection (Figure 7). Most 
operators will inject up to three levels at a single sitting. 
During the procedure bone biopsies may also be taken to 
conﬁ  rm the suspected diagnoses.
Kyphoplasty is an alternative technique, which is similar 
to vertebroplasty but includes the additional step of introduc-
ing a high-pressure balloon into the vertebral body to form a 
cavity into which cement is injected. This technique produces 
a small but measurable restoration of the body height of 
the collapsed vertebrae.84 It also reduces the risk of cement 
leakage seen with vertebroplasty due to the formation of a 
cavity allowing low-pressure cement injection.82 Several 
large scale nonrandomized controlled trials and observa-
tional studies of vertebroplasty and/or kyphoplasty against 
best medical therapy have demonstrated their relative safety 
and superior effectiveness in treating painful osteoporotic 
vertebral fractures.85,86
As with any interventional procedure patients should be 
assessed clinically to conﬁ  rm their suitability. The vertebral 
fracture should be conﬁ  rmed as the likeliest cause for the 
patients’ pain and other causes such as degenerative changes 
and radiculopathy should be considered and excluded. Diffuse 
pain is unlikely to settle with vertebroplasty or kyphoplasty 
and symptoms should also correlate with the radiological 
ﬁ  ndings. Patients may initially be diagnosed on plain ﬁ  lm 
ﬁ  ndings, however magnetic resonance imaging (MRI) is also 
normally undertaken to conﬁ  rm edema within the fracture 
site (a good indicator that vertebroplasty will be effective) 
and assess for spinal cord involvement. CT and technetium 
99m-pertechnetate bone scintigraphy have also been used.87 
Contraindications include fractures which are asymptomatic 
or improving on medical therapy, as a prophylactic measure Clinical Interventions in Aging 2009:4 12
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for osteoporosis, infection, myelopathy related to retropulsed 
fragments and uncorrected coagulopathy.88
Complications are more common in the treatment of 
metastatic compared to osteoporotic disease. The incidence 
of serious complications has been reported at 0.9% including 
severe cement leakage or neurological symptoms requiring 
surgery.83 Cement leakage is in fact a common phenomenon 
(41%) and sometimes a small amount may indicate that 
optimal ﬁ  lling of the vertebral body has been achieved. 
The incidence of cement embolism is thought to be very 
low (0.1%) and symptomatic cases are conﬁ  ned to case 
reports.89 The risk of fracture to adjacent vertebral bodies 
following vertebroplasty is also recognized. Although the 
absolute risk is unclear the increased risk may be as high as 
5-fold.90 Kyphoplasty, which reduces the degree of deformity, 
may help to reduce this risk. Pneumothorax and paraspinal 
haematoma are further risks when the procedure is performed 
in the thoracic spine.87
These procedures are characterized by an immediate 
analgesic effect91 with the large majority experiencing pain 
relief within hours of the procedure.82 Despite this, the 
cause for pain relief is poorly understood. Bone cement 
(polymethylmethylacrylate [PMMA]), which achieves 
90% of its ultimate strength within one hour of injection,92 
may immobilize fracture fragments and have a heat effect 
on nerve endings.83 However no correlation has been found 
between the amount of cement injected or indeed the degree 
of vertebral body height restored and pain relief.93 Many 
studies now support the use of these techniques although 
long-term studies and head-to-head randomized clinical trials 
are still lacking.94 Short- to mid-term follow up has shown 
a 90% improvement in pain levels 18 months following 
vertebroplasty for osteoporotic fractures.92 A study of 
173 patients with osteoporotic vertebral compression fractures 
found signiﬁ  cant pain reduction immediately following the 
procedure and 82% reported marked to complete resolution of 
Figure 7 Example of percutaneous vertebroplasty for lumbar osteoporotic fracture.  A 72-year-old female patient with severe back pain. (a) Lateral lumbar X-ray demonstrates 
a fractured L2 vertebral body (white arrow) (b) High signal on STIR MR sequence due to bone edema, compatible with a recently onset osteoporotic fracture (white arrow) 
(c–d) Percutaneous unipedicular vertebroplasty and cement stabilization of the affected body (Optimed Vertebroplasty System, Pyramed, Esher, United Kingdom). A bone 
biopsy specimen was taken before cement injection (white arrowheads) to exclude any underlying malignancy. The patient experienced immediate post-operative pain relief 
and was ambulated the following day.Clinical Interventions in Aging 2009:4 13
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original symptoms at 2 years independent of whether single 
or multiple levels were treated.95 A study of 112 patients with 
up to 3 years follow up found signiﬁ  cantly less analgesia 
used and a high rate of patient satisfaction.96 Of particular 
relevance to the elderly, one study has demonstrated 69% 
of nonambulatory patients becoming ambulatory following 
vertebroplasty due to signiﬁ  cant pain relief.91 A review of 
the literature on the treatment of metastases and debilitating 
pain has demonstrated pain relief in 50%–97% of patients 
following vertebroplasty. This outcome is similar to the 
ones reported for surgical treatment.87,97 A pooled analysis 
of 19 studies has demonstrated a 67.9% reduction in reported 
pain using a visual analogue scale following vertebroplasty 
for all causes.83 A systematic comparative review of vertebro-
plasty and kyphoplasty suggests that both provide similar pain 
relief although kyphoplasty may have beneﬁ  ts in functionality 
and quality of life with lower rates of cement leakage, and 
less neurologic and pulmonary complications.85
Conclusion
Minimally invasive interventional radiological procedures 
may be applied for the curative or palliative treament of a 
variety of disorders in the elderly population. In comparison 
to surgery, they are related with signiﬁ  cantly less mortality 
and morbidity, while being equally effective. This is 
of extreme importance in the setting of elderly patients 
suffering from multiple comorbidities and associated risk 
factors. Physicians actively involved in the care of elderly 
patients, especially octogenarians, need to be aware of the 
range of image-guided percutaneous treatment options 
including their indications, efﬁ  cacy, results and potential 
complications.
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